San Mateo, CA – January, 25 2022 – Calysta, Inc. World-leading alternative protein producer, Calysta, has signaled its future intentions with the appointment of Dr Lori Giver, as Chief Science and Sustainability Officer.
Dr Giver first joined Calysta in 2013 as Vice President, Biological Engineering, before being appointed Vice President, Research and Development in 2019. In her new role, Lori will join the executive team and will play a key role in fulfilling Calysta’s ongoing commitment to the highest levels of sustainability.
Welcoming Lori into her new role, Calysta’s President, CEO and Co-Founder, Dr Alan Shaw, said: “This is a very important appointment for Calysta. Lori has played a pivotal role in our story so far and takes up this new position at a very exciting time for the business, with our first commercial-scale production facility to open in China later this year.
“Producing a sustainable protein that has no impact on biodiversity is a huge priority for us and this appointment underlines our determination to lower our footprint even further and fulfil our ongoing mission of making more from less.”
Like Alan Shaw, Dr Giver came to Calysta from Codexis, where she held a number of positions including Vice President of Systems Biology, Senior Director of Technology and Innovation, and Manager of Market Development. Lori completed post-doctoral studies with 2018 Nobel Prize for Chemistry winner Dr Frances Arnold. She is an author on numerous scientific publications and over 50 patents and patent applications.
On her appointment, Dr Giver said: “Calysta’s mission is to make more from less and I am passionate about fulfilling that ambition, which is why this new role is so exciting.
“By 2050 there will be two billion more people to feed on planet earth, but many of our existing food production techniques are unsustainable. The status quo cannot continue. We must strive to produce lower impact foods and feeds if we are to meet global demand. Calysta has a big role to play in addressing this and I will be working hard to improving our sustainability profile even further for current and future products from our proprietary fermentation platform.”
Calysta is developing a family of natural, sustainable and traceable feed ingredients for fish, livestock and pets, produced by fermenting natural gas with a naturally occurring bacteria. It requires no arable land, uses no plant or animal matter in its production and uses very little water, supporting global food security and helping feed an increasing population in a sustainable way. The first of these products, FeedKind® protein, is tailored for the aquaculture and livestock markets.
Calysta’s 50/50 joint venture with Adisseo, Calysseo, is in the process of building the world’s first FeedKind commercial production facility in Chongqing, China, with 20,000 tonnes to come onto the market this year, increasing to 80,000 tonnes shortly thereafter.
Investors in Calysta include bp, Adisseo, Temasek, AquaSpark, Mitsui and Cargill. For more information about Calysta, visit www.Calysta.com. Join the newsletter at www.FeedKind.com.
Calysta, Inc., San Mateo, CA, is a biotechnology company working towards a future where the world’s growing population has guaranteed food security. Calysta’s aim is to make more from less by fermenting natural gas to create new feed and food products, creating sustainable, high value nutritional ingredients that don’t interfere with the human food chain.
FeedKind®, is made using very little water and no agricultural land by fermenting natural gas, an abundant source of energy, to create a safe, nutritious, traceable and affordable protein. Produced via a natural fermentation, it is non-GMO, price competitive with existing sources of protein and produced to the highest quality standards. FeedKind has been commercially validated through extensive customer trials in aquaculture and agriculture.
Contacts: Calysta – Steven Flanagan, (+44) 141 343 3250, [email protected] or Calysta Media Information, [email protected]